Elesclomol (STA-4783)

製品コードS1052

Elesclomol (STA-4783)化学構造

分子量(MW):400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

サイズ 価格(税別)  
JPY 31540.00
JPY 28220.00
JPY 53120.00
JPY 161020.00

カスタマーフィードバック(4)

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
ターゲット
HSP70 [1]
(Cell-free assay)
体外試験

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NXzK[JRuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1HRSmlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP M3i2SHNCVkeHUh?=
CAL-51 cell MlPCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnsTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?= M{P3bnNCVkeHUh?=
ABC-1 cell NYXzT5VUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{fYTmlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?= NUi1S5ExW0GQR1XS
A2780 cell M3vu[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MkD5V2FPT0WU
ES1 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{S5JI5O NV3jWYI5W0GQR1XS
HUTU-80 cell NEDsUldIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4L5XmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzlzIH7N NUT6cJZTW0GQR1XS
NCI-H292 cell NXWweIZ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;yTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDh4IH7N M3[0eXNCVkeHUh?=
NB69 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmXzTY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yNkBvVQ>? M3zQS3NCVkeHUh?=
ES8 cell NHP4dZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLETY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkOyJI5O MVPTRW5ITVJ?
BCPAP cell M2KyTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkXlTY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Qhdk1? MmnvV2FPT0WU
T-24 cell M2XIT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O NV;hUWlYW0GQR1XS
EW-16 cell NUPlXW5jT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? M3nXTHNCVkeHUh?=
OVCAR-5 cell NGOwdWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIfMe2VKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh|IH7N M375W3NCVkeHUh?=
SF126 cell NEm4ZXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OUBvVQ>? NID3cZZUSU6JRWK=
KP-4 cell NVfnVGptT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWX3ZWNIUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?= M3f0cnNCVkeHUh?=
GAMG cell NGDFT4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33aOGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVEhdk1? MUjTRW5ITVJ?
HOS cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1fxOWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61N{BvVQ>? NETlc5FUSU6JRWK=
CHL-1 cell Mn;PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUDJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj64NUBvVQ>? Mk\FV2FPT0WU
AGS cell M2ezZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfWTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lki2JI5O MXjTRW5ITVJ?
MDA-MB-157 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3joVWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUKgcm0> NF7sTJdUSU6JRWK=
HSC-3 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MknWTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? MoDCV2FPT0WU
CAL-72 cell NWHZWmlIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? M4O4VnNCVkeHUh?=
NBsusSR cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHQTpJpUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=> NEH4RnhUSU6JRWK=
ES7 cell M1v1bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;YTGVKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? NF:xPZZUSU6JRWK=
H-EMC-SS cell MnzLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4THb2lvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MV\TRW5ITVJ?
NCI-H1703 cell MmLZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHCb|NCUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4JI5O M1WyPHNCVkeHUh?=
BHT-101 cell MoHqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUjJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlczKG6P NWPK[3hMW0GQR1XS
SK-OV-3 cell NVnSc4tCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXzsSFhpUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> NI\qXVZUSU6JRWK=
EW-24 cell NIXPOItIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64N{BvVQ>? M{PKR3NCVkeHUh?=
PSN1 cell MmjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLFfZM{UW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45PCCwTR?= MVvTRW5ITVJ?
OVCAR-8 cell NHm3VFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk6KG6P NFjS[|lUSU6JRWK=
NCI-H1563 cell M1zzNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2OwUmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> MkLqV2FPT0WU
SW756 cell M13kOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIjmPXlKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?= M4KyR3NCVkeHUh?=
A375 cell NH\MdW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\STY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? NXjoT|VVW0GQR1XS
Ca9-22 cell NF3wWVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlUhdk1? MkLBV2FPT0WU
SW1990 cell M{frcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|Ihdk1? NVXINHE2W0GQR1XS
ES4 cell M3uyfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIXkW4dKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|khdk1? MXTTRW5ITVJ?
HCE-T cell MoPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{e5e2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ2KG6P MmPWV2FPT0WU
MOLT-16 cell M4LtVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWrkem54UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53MzDuUS=> NEXReGxUSU6JRWK=
HSC-4 cell NG\mZmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PEbWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlghdk1? MnzUV2FPT0WU
NCI-SNU-1 cell MojFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmXSTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njh4IH7N NXrF[2h5W0GQR1XS
EW-11 cell Mk\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65JI5O MkfEV2FPT0WU
HT-1080 cell NHPqNVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\zTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QSCwTR?= NW\0Nlg4W0GQR1XS
MES-SA/Dx5 cells MmnnR5l1d3SxeHnjbZR6KGG|c3H5 NWfVepRLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O NVK0OndZOjN7M{e5PFE>
SW1710 cell NXPoOW5PT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml\PTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P NGruOFFUSU6JRWK=
EW-1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jN[2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlQhdk1? NGriN5lUSU6JRWK=
BV-173 cell NHzveXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFm0cnVKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= NUDlcI5WW0GQR1XS
TE-8 cell MoLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoTpTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60NUBvVQ>? NI[xeHRUSU6JRWK=
G-401 cell M3;ZVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlvGTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFMhdk1? NVTLbGZYW0GQR1XS
KOSC-2 cell NYDtRZJCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{fCb2lvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?= MonmV2FPT0WU
HuCCT1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fEN2lvcGmkaYTpc44hd2ZiaIXtZY4hUHWFQ2SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OiCwTR?= MofoV2FPT0WU
FADU cell NH3pdlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzqOopVUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PiCwTR?= MmLFV2FPT0WU
MHH-ES-1 cell M{Oxbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\6bpNwUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> NYXRNGtYW0GQR1XS
ES3 cell MlfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLHTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O NFPsUo9USU6JRWK=
OVCAR-4 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnj6TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45PyCwTR?= Mm[xV2FPT0WU
HD-MY-Z cell M3nVS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P MoDWV2FPT0WU
human JAR cell NXGyb4E{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUegcm0> NH;PeFBUSU6JRWK=
A427 cell NF;vRYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIXvXIxKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA4KG6P MoDzV2FPT0WU
697 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTpXpZ1UW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE{KG6P NUfQeXhKW0GQR1XS
OVCAR-3 cell NHzTSGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnmwTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P NELDRZZUSU6JRWK=
human NB14 cell MlPWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\ZWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOlQhdk1? M1TYOHNCVkeHUh?=
GB-1 cell NVnmOVNiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFjnNmpKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlcyKG6P NXzwfXpiW0GQR1XS
COR-L105 cell MmTpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= NXvWSlN6W0GQR1XS
647-V cell NHH5[oRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWnnbpplUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?= NV\UU|RtW0GQR1XS
human K5 cell NYOwZ4lST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?= MVTTRW5ITVJ?
DMS-273 cell M33VR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFP0PI9KdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N MofpV2FPT0WU
UM-UC-3 cell M2H6UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1z6SWlvcGmkaYTpc44hd2ZiaIXtZY4hXU1vVVOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODZibl2= NWr0VogzW0GQR1XS
HEL cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> NFLzSpRUSU6JRWK=
human KU-19-19 cell M1rNVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXIdFNCUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> NFnJT3VUSU6JRWK=
MC-IXC cell Mny2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mmq3TY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlE4KG6P NIjlZWpUSU6JRWK=
human H4 cell M2O2fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1jZb2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O M1rMXXNCVkeHUh?=
NUGC-3 cell MkXzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuN|Mhdk1? NUjLVJdLW0GQR1XS
CHP-212 cell NWDQU2pST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUDhOFV3UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> NYjEVWNxW0GQR1XS
human SW982 cell NEjIeYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LBWWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P MkLkV2FPT0WU
C-33-A cell NYjyNoxLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVghdk1? MUDTRW5ITVJ?
PC-3 cell NIrZdXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mny4TY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVQ>? MXLTRW5ITVJ?
COLO-684 cell MnT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlL6TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= NUnuc|JyW0GQR1XS
SNU-387 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVLUUYRGUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=> MXjTRW5ITVJ?
U251 cell M4njTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4fsUWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? NUPUeWdyW0GQR1XS
A673 cell NETtSGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH:1U2hKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P MX3TRW5ITVJ?
human T47D cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUjJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? MXfTRW5ITVJ?
A549 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI\3cJpKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43KG6P NVX1WVlUW0GQR1XS
PC-14 cell NF[5dmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHBENTF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuO|Mhdk1? MlnRV2FPT0WU
A704 cell NVnqSXVRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7TTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuOFUhdk1? Mo\LV2FPT0WU
MCF7 cell NUf6UmJ1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3W2VmlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOxMlM3KG6P NXHQe3M5W0GQR1XS
PC3 cells NW\kOFhrTnWwY4Tpc44h[XO|YYm= Mo\TTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> NUHEUmQxOjF|NEG2O|U>
F-36P cells M{\1fnBzd2yrZnXyZZRqd25iYYPzZZk> NVTJPYJvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?= MnW3NlE{PDF4N{W=
OCI-AML2 cells NHPqc3FRem:uaX\ldoF1cW:wIHHzd4F6 NHrBOYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN Mkm1NlE{PDF4N{W=
K562 cells M4HQdXBzd2yrZnXyZZRqd25iYYPzZZk> NVrjWmxtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? NYTVZng1OjF|NEG2O|U>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: Hs294T, HSB2, and Ramos
  • 濃度: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • 反応時間: 18, or 24 hours
  • 実験の流れ: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~100 mg/kg
  • 投与方法: Intravenous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
1% DMSO+30% polyethylene glycol+1% Tween 80
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 400.5
化学式

C19H20N4O2S2

CAS No. 488832-69-5
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How can we use the compound for in vivo mouse studies?

  • 回答:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90)シグナル伝達経路

相関HSP (e.g. HSP90)製品

Tags: Elesclomol (STA-4783)を買う | Elesclomol (STA-4783) ic50 | Elesclomol (STA-4783)供給者 | Elesclomol (STA-4783)を購入する | Elesclomol (STA-4783)費用 | Elesclomol (STA-4783)生産者 | オーダーElesclomol (STA-4783) | Elesclomol (STA-4783)化学構造 | Elesclomol (STA-4783)分子量 | Elesclomol (STA-4783)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID